KRAS(G12C) Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

PURPOSE: KRAS(G12C) is the most common KRAS mutation in primary lung adenocarcinoma (LUAD). Phase I clinical trials have demonstrated encouraging clinical activity of KRAS(G12C) inhibitors in the metastatic setting. We investigated disease-free survival (DFS) and tumor genomic features in patients w...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Jones, Gregory D., Caso, Raul, Tan, Kay See, Mastrogiacomo, Brooke, Sanchez-Vega, Francisco, Liu, Yuan, Connolly, James G., Murciano-Goroff, Yonina R., Bott, Matthew J., Adusumilli, Prasad S., Molena, Daniela, Rocco, Gaetano, Rusch, Valerie W., Sihag, Smita, Misale, Sandra, Yaeger, Rona, Drilon, Alexander, Arbour, Kathryn C., Riely, Gregory J., Rosen, Neal, Lito, Piro, Zhang, Haiying, Lyden, David C., Rudin, Charles M., Jones, David R., Li, Bob T., Isbell, James M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8102372/
https://ncbi.nlm.nih.gov/pubmed/33593884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4772
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller